|
06 Jan 2021 |
Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist
|
|
06 Jan 2021 |
AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME)
|
|
05 Jan 2021 |
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
|
|
05 Jan 2021 |
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
|
|
05 Jan 2021 |
US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
|
|
30 Dec 2020 |
Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers
|
|
29 Dec 2020 |
Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial
|
|
29 Dec 2020 |
Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
|
|
23 Dec 2020 |
Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
|
|
23 Dec 2020 |
ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury
|
|
22 Dec 2020 |
ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate
|
|
22 Dec 2020 |
The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
|
|
18 Dec 2020 |
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss
|
|
18 Dec 2020 |
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules
|
|
18 Dec 2020 |
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
|
|
18 Dec 2020 |
Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management
|
|
17 Dec 2020 |
Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy
|
|
16 Dec 2020 |
Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes
|
|
16 Dec 2020 |
Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide
|
|
16 Dec 2020 |
Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer
|
|
11 Dec 2020 |
Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
|
|
10 Dec 2020 |
Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
|
|
09 Dec 2020 |
Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
|
|
08 Dec 2020 |
Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
|
|
08 Dec 2020 |
Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting
|
